ETFs: Drug Pricing Policy Shapes PPH Risks in 2026
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Using sentiment indicators with index level data combines psychology and price to strengthen analysis. This overview provides steps to integrate both streams.
26,603 articlesThe VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
In 2022, the S&P 500 tumbled as inflation hung over markets, but healthcare ETFs held up better. This piece examines ...
Tech leaders are shifting in 2026, prompting a clash between QQQ and VGT for access to Big Tech. This report breaks d...
A long dangerous heat wave grips the central and eastern U.S., pushing temperatures into the 90s and 100s through the...
As U.S.–Iran tensions flare, energy prices surge and corporate boards adjust risk, liquidity and strategy in a newly ...
A trio of S&P 500 dividend stocks that pay monthly dividends are outperforming the broader index, delivering reliable...
A senior Iranian official publicly mocks Trump's appeal to help reopen the Hormuz Strait as tensions intensify, with ...
ARTY leads humanoid-robot ETFs in 2026, outpacing BOTT and ROBO as investors chase AI software momentum. This shift h...
A disciplined, calendar-driven approach to investing is gaining ground as markets swing on tariff news and rate moves...
A seasoned investor reveals a stubborn bet on Microsoft, arguing that the company’s dual engine—legacy software profi...
Investors face a clear choice: concentrate on U.S. real estate with ICF or embrace international markets through VNQI...
A new growth-focused ETF with a 0.03% expense ratio has posted strong five-year outperformance versus the S&P 500, le...